CAM
RCKT icon

Cormorant Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Cormorant Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300,000
Closed -$8.08M – 61
2024
Q1 		$8.08M Sell
300,000
-150,000
-33% -$4.26M 0.35% 48
2023
Q4 		$13.5M Hold
450,000
– – 0.64% 36
2023
Q3 		$9.22M Sell
450,000
-418,550
-48% -$7.61M 0.54% 36
2023
Q2 		$17.3M Hold
868,550
– – 0.97% 28
2023
Q1 		$14.9M Hold
868,550
– – 0.98% 29
2022
Q4 		$17M Hold
868,550
– – 1.14% 30
2022
Q3 		$13.9M Hold
868,550
– – 0.97% 37
2022
Q2 		$12M Hold
868,550
– – 0.9% 36
2022
Q1 		$13.8M Hold
868,550
– – 1.06% 28
2021
Q4 		$19M Sell
868,550
-100,000
-10% -$2.73M 1.13% 26
2021
Q3 		$28.9M Hold
968,550
– – 1.18% 26
2021
Q2 		$42.9M Sell
968,550
-400,000
-29% -$17.4M 1.46% 24
2021
Q1 		$60.7M Hold
1,368,550
– – 1.35% 17
2020
Q4 		$75.1M Hold
1,368,550
– – 1.79% 18
2020
Q3 		$31.3M Sell
1,368,550
-100,000
-7% -$2.46M 1.2% 29
2020
Q2 		$30.7M Sell
1,468,550
-100,000
-6% -$1.8M 1.17% 27
2020
Q1 		$21.9M Sell
1,568,550
-268,719
-15% -$5.32M 1.02% 31
2019
Q4 		$41.8M Sell
1,837,269
-286,491
-13% -$4.78M 1.67% 20
2019
Q3 		$24.7M Buy
2,123,760
+49,165
+2% +$610K 1.51% 23
2019
Q2 		$31.1M Buy
2,074,595
+374,595
+22% +$6.54M 1.79% 19
2019
Q1 		$29.8M Sell
1,700,000
-245,659
-13% -$3.88M 2.02% 21
2018
Q4 		$28.8M Buy
1,945,659
+445,000
+30% +$7.39M 2.34% 14
2018
Q3 		$36.9M Sell
1,500,659
-19,231
-1% -$417K 2.4% 14
2018
Q2 		$29.8M Sell
1,519,890
-1
-0% -$19 2.21% 15
2018
Q1 		$28.5M Buy
+1,519,891
New +$24.8M 2.12% 12

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's RCKT Position: Q2 2024 in Review

Cormorant Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 300,000 shares — an estimated $8.08M sold.

Cormorant Asset Management first reported a position in RCKT in Q1 2018 and held it in 25 quarters. The position peaked at $75.1M in Q4 2020. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

  • Cormorant Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 300,000 Rocket Pharmaceuticals shares in Q2 2024, an estimated $8.08M.
  • Cormorant Asset Management first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 25 quarters.
  • Cormorant Asset Management's Rocket Pharmaceuticals position peaked at $75.1M in Q4 2020.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.